These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 26997452)
41. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients. Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG Ann Surg Oncol; 2008 Mar; 15(3):906-14. PubMed ID: 18163171 [TBL] [Abstract][Full Text] [Related]
42. Neoadjuvant multidrug chemotherapy including high-dose methotrexate modifies VEGF expression in osteosarcoma: an immunohistochemical analysis. Rossi B; Schinzari G; Maccauro G; Scaramuzzo L; Signorelli D; Rosa MA; Fabbriciani C; Carlo B BMC Musculoskelet Disord; 2010 Feb; 11():34. PubMed ID: 20158913 [TBL] [Abstract][Full Text] [Related]
43. Does expression of glucose transporter protein-1 relate to prognosis and angiogenesis in osteosarcoma? Kubo T; Shimose S; Fujimori J; Furuta T; Arihiro K; Ochi M Clin Orthop Relat Res; 2015 Jan; 473(1):305-10. PubMed ID: 25193692 [TBL] [Abstract][Full Text] [Related]
44. Osteosarcomas after the age of 50: a clinicopathologic study of 64 cases--an experience in northern Japan. Okada K; Hasegawa T; Nishida J; Ogose A; Tajino T; Osanai T; Yanagisawa M; Hatori M Ann Surg Oncol; 2004 Nov; 11(11):998-1004. PubMed ID: 15525829 [TBL] [Abstract][Full Text] [Related]
45. Usefulness of β-catenin expression in the differential diagnosis of osteosarcoma, osteoblastoma, and chondroblastoma. Erdogan KE; Pacheco M; Gambarotti M; Magagnoli G; Sbaraglia M; Frisoni T; Righi A; Dei Tos AP Virchows Arch; 2021 Sep; 479(3):529-535. PubMed ID: 33511430 [TBL] [Abstract][Full Text] [Related]
46. Spontaneous necrosis in osteosarcoma. Springfield DS; Schakel ME; Spanier SS Clin Orthop Relat Res; 1991 Feb; (263):233-7. PubMed ID: 1993380 [TBL] [Abstract][Full Text] [Related]
47. Noninvasive assessment of response to neoadjuvant chemotherapy in osteosarcoma of long bones with diffusion-weighted imaging: an initial in vivo study. Wang CS; Du LJ; Si MJ; Yin QH; Chen L; Shu M; Yuan F; Fei XC; Ding XY PLoS One; 2013; 8(8):e72679. PubMed ID: 23991141 [TBL] [Abstract][Full Text] [Related]
48. Correlation between fluid-fluid levels on initial MRI and the response to chemotherapy in stage IIb osteosarcoma. Jeon DG; Cho WH; Song WS; Kong CB; Cho SH; Lee JW; Lee SY Ann Surg Oncol; 2014 Jun; 21(6):1956-62. PubMed ID: 24577812 [TBL] [Abstract][Full Text] [Related]
49. pFAK-Y397 overexpression as both a prognostic and a predictive biomarker for patients with metastatic osteosarcoma. Thanapprapasr K; Nartthanarung A; Thanapprapasr D; Jinawath A PLoS One; 2017; 12(8):e0182989. PubMed ID: 28846700 [TBL] [Abstract][Full Text] [Related]
50. Correlation between Prognostic Factors and the Histopathological Response to Neoadjuvant Chemotherapy in Osteosarcoma: A Retrospective Study. Prabowo Y; Setiawan I; Kamal AF; Kodrat E; Labib Zufar ML Int J Surg Oncol; 2021; 2021():8843325. PubMed ID: 33996154 [TBL] [Abstract][Full Text] [Related]
51. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy. Baldini N; Scotlandi K; Serra M; Picci P; Bacci G; Sottili S; Campanacci M J Orthop Res; 1999 Sep; 17(5):629-32. PubMed ID: 10569469 [TBL] [Abstract][Full Text] [Related]
52. Tumor necrosis predicts survival following neo-adjuvant chemotherapy for hepatoblastoma. Venkatramani R; Wang L; Malvar J; Dias D; Sposto R; Malogolowkin MH; Mascarenhas L Pediatr Blood Cancer; 2012 Sep; 59(3):493-8. PubMed ID: 22190448 [TBL] [Abstract][Full Text] [Related]
53. Morphological aspects of the hepatic response to neoadjuvant therapy. Fernández-Aceñero MJ; Cortés-Guiral D; Muñoz LE; Martínez-Useros J; Pastor-Idoate C Pathol Res Pract; 2015 Sep; 211(9):665-70. PubMed ID: 26163186 [TBL] [Abstract][Full Text] [Related]
54. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Uhl M; Saueressig U; van Buiren M; Kontny U; Niemeyer C; Köhler G; Ilyasov K; Langer M Invest Radiol; 2006 Aug; 41(8):618-23. PubMed ID: 16829744 [TBL] [Abstract][Full Text] [Related]
55. Comments on Bu et al. "P16(INK₄a) overexpression and survival in osteosarcoma patients: a meta analysis". Yan MM; Ni JD Int J Clin Exp Pathol; 2015; 8(6):7617-8. PubMed ID: 26261680 [TBL] [Abstract][Full Text] [Related]
56. Proximal location in extremity long bones is a poor prognostic factor for osteosarcoma: A retrospective cohort study of 153 patients. Cates JM; Schoenecker JG Acta Oncol; 2016 Aug; 55(8):1036-9. PubMed ID: 27145235 [TBL] [Abstract][Full Text] [Related]
57. Tissue necrosis after chemotherapy in osteosarcoma as the important prognostic factor. Sami SH; Rafati AH; Hodjat P Saudi Med J; 2008 Aug; 29(8):1124-9. PubMed ID: 18690304 [TBL] [Abstract][Full Text] [Related]
58. [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients]. Bielack S; Kempf-Bielack B; Schwenzer D; Birkfellner T; Delling G; Ewerbeck V; Exner GU; Fuchs N; Göbel U; Graf N; Heise U; Helmke K; von Hochstetter AR; Jürgens H; Maas R; Münchow N; Salzer-Kuntschik M; Treuner J; Veltmann U; Werner M; Winkelmann W; Zoubek A; Kotz R Klin Padiatr; 1999; 211(4):260-70. PubMed ID: 10472560 [TBL] [Abstract][Full Text] [Related]
59. Prognostic value of p53 alterations in human osteosarcoma: a meta analysis. Yao D; Cai GH; Chen J; Ling R; Wu SX; Li YP Int J Clin Exp Pathol; 2014; 7(10):6725-33. PubMed ID: 25400752 [TBL] [Abstract][Full Text] [Related]
60. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Bacci G; Mercuri M; Longhi A; Ferrari S; Bertoni F; Versari M; Picci P Eur J Cancer; 2005 Sep; 41(14):2079-85. PubMed ID: 16115755 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]